Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EPS (Weighted Average and Diluted) (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.04 in Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) rose 78.95% year-over-year to -$0.04; the TTM value through May 2025 reached -$1.27, down 484.85%, while the annual FY2025 figure was -$1.27, 484.85% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.04 in Q2 2025 per LFCR's latest filing, up from -$0.47 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.45 in Q4 2023 and bottomed at -$3.56 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.46, with a median of -$0.24 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 11766.67% in 2022, then skyrocketed 481.82% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.12 in 2021, then plummeted by 458.33% to -$0.43 in 2022, then skyrocketed by 204.65% to $0.45 in 2023, then crashed by 151.11% to -$0.23 in 2024, then skyrocketed by 82.61% to -$0.04 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.04 in Q2 2025, -$0.47 in Q1 2025, and -$0.23 in Q4 2024.